Rite Aid Data Breach Lawsuit Says 2.2 Million People Impacted by 2024 Cyberattack
July 26, 2024 Rite Aid faces a class action lawsuit over a reported 2024 data breach during which the personal info of roughly 2.2 million people was stolen.
July 26, 2024 Rite Aid faces a class action lawsuit over a reported 2024 data breach during which the personal info of roughly 2.2 million people was stolen.
November 29, 2021 A class action alleges Tugaboos Toddler Beginnings formula is misleadingly labeled in that consumers are led to believe it is nutritionally appropriate for toddlers.
November 2, 2021 Rite Aid faces a lawsuit over a Feb. 2021 data breach during which the personal information of thousands of patients was reportedly exposed to unauthorized parties.
July 2, 2020 A class action challenges the manner in which Rite Aid markets, prices and sells its brand of acetaminophen pain and fever relievers for infants and children.
August 5, 2019 Rite Aid is being sued over alleged discrimination against the blind and violations of the Americans with Disabilities Act due to the possible inaccessibility of its stores.
June 13, 2019 Two healthcare plans have joined the ranks of those suing Big Pharma heavyweights over their alleged contributions to the national opioid crisis that has devastated the nation.
March 29, 2019 Rite Aid Corporation has been hit with a proposed class action in California that claims the drugstore chain collects donations from customers without their consent.
December 11, 2018 Mylan and Rite Aid are facing a class action that claims the companies respectively manufactured and sold generic valsartan medications despite possessing knowledge that the drugs were contaminated with probable carcinogen N-nitrosodiethylamine (NDEA).
January 26, 2018 Rite Aid Corporation is facing another proposed class action alleging it engineered an 'unfair and deceptive price scheme' to overcharge customers paying for generic drugs through third-party insurance plans.
June 30, 2017 According to a recent class action, Rite Aid runs a deceptive pricing scheme in which it undercuts the 'usual and customary' prices for generic drugs.